Parameters | Patients | sLAG-3+ cells infiltration | iLAG-3+ cells infiltration | |||||
No. | % | Low (n=70) | High (n=71) | P value* | Negative (n=73) | Positive (n=68) | P value* | |
(<10 cells/HPF) | (≥10 cells/HPF) | (<1 cells/HPF) | (≥1 cells/HPF) | |||||
Age at surgery (year) | 0.195† | 0.678† | ||||||
Median (IQR) | 62.0 (56–71) | 61.5 (54–72) | 64.0 (58–71) | 62.0 (56–72) | 62.5 (56–69) | |||
Gender | 0.191 | 0.248 | ||||||
Male | 117 | 83 | 61 | 56 | 58 | 59 | ||
Female | 24 | 17 | 9 | 15 | 15 | 9 | ||
Tumor size (cm) | 0.291† | 0.431† | ||||||
Median (IQR) | 3.5 (2.5–5.0) | 4.0 (2.3–6.0) | 3.5 (2.5–4.0) | 3.0 (2.5–5.0) | 4.0 (2.5–5.0) | |||
AJCC stage | 0.002 | 0.679 | ||||||
II | 87 | 61.7 | 53 | 34 | 45 | 42 | ||
III | 46 | 32.6 | 16 | 30 | 25 | 21 | ||
IV | 8 | 5.7 | 1 | 7 | 3 | 5 | ||
pT stage | 0.014 | 0.170 | ||||||
pT2 | 90 | 63.8 | 53 | 37 | 47 | 43 | ||
pT3 | 30 | 21.3 | 10 | 20 | 12 | 18 | ||
pT4 | 21 | 14.9 | 7 | 14 | 14 | 7 | ||
pN stage | 0.063 | 0.482 | ||||||
pN0 | 133 | 94.3 | 69 | 64 | 70 | 63 | ||
pN+ | 8 | 5.7 | 1 | 7 | 3 | 5 | ||
Grade | 0.067 | 0.480 | ||||||
Low | 24 | 17 | 16 | 8 | 14 | 10 | ||
High | 117 | 83 | 54 | 63 | 59 | 58 | ||
LVI | 0.070 | 0.978 | ||||||
Absent | 52 | 36.9 | 31 | 21 | 27 | 25 | ||
Present | 89 | 63.1 | 39 | 50 | 46 | 43 | ||
ACT | 0.447 | 0.359 | ||||||
Applied | 69 | 48.9 | 32 | 37 | 33 | 36 | ||
Not applied | 72 | 51.1 | 38 | 34 | 40 | 32 |
Tumor stage was updated according to AJCC 2017 classification.
*P value from Fisher’s exact test was used when data fail to meet the requirement of χ2 test; significant p value < 0.05 was shown in bold.
†Mann-Whitney U test.
ACT, adjuvant chemotherapy; AJCC, American Joint Committee on Cancer; HPF, high-power field; iLAG-3+, intraepithelial LAG-3+; LVI, lymphovascular invasion; sLAG-3+, stromal LAG-3+.